<DOC>
	<DOC>NCT00195260</DOC>
	<brief_summary>To evaluate the safety and tolerability of oral SKI-606 (bosutinib) administered on a daily schedule to subjects with advanced malignant solid tumors and to define a maximum tolerated dose (MTD) in this subject population.</brief_summary>
	<brief_title>Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Advanced or recurrent solid malignancy confirmed histologically or cytologically for which no effective therapy is available. Eastern Cooperative Oncology Group (ECOG) performance status of 0 1. Measurable disease as outlined by the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Other inclusion applies. Use of any systemic antitumor agents or any investigational agent within 28 days before the first dose of test article is administered. Prior exposure to SKI606 or any other Srckinase inhibitor, major surgery or radiotherapy within 14 days before the first dose of test article (recovery from previous surgery should be complete before day 1). Active central nervous system (CNS) metastases, as indicated by clinical symptoms, cerebral edema, requirement for corticosteroids and/or progressive growth (Treated CNS metastases must be stable for &gt;= 2 weeks before day 1). Other exclusion applies.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Solid tumors</keyword>
</DOC>